title: Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review.
abstract: Systemic anthrax is associated with high mortality. Current national guidelines, developed for the individualized treatment of systemic anthrax, outline the use of combination intravenous antimicrobials for a minimum of 2 weeks, bactericidal and protein synthesis inhibitor antimicrobials for all cases of systemic anthrax, and at least 3 antimicrobials with good blood-brain barrier penetration for anthrax meningitis. However, in an anthrax mass casualty incident, large numbers of anthrax cases may create challenges in meeting antimicrobial needs. To further inform our understanding of the role of antimicrobials in treating systemic anthrax, a systematic review of the English-language literature was conducted to identify cases of systemic anthrax treated with antimicrobials for which a clinical outcome was recorded. A total of 149 cases of systemic anthrax were identified. Among the identified 59 cases of cutaneous anthrax, 33 were complicated by meningitis (76% mortality), while 26 simply had evidence of the systemic inflammatory response syndrome (4% mortality); 21 of 26 (81%) of this latter group received monotherapy. Subsequent analysis regarding combination antimicrobial therapy was restricted to the remaining 123 cases of more severe anthrax (overall 67% mortality). Recipients of combination bactericidal and protein synthesis inhibitor therapy had a 45% survival versus 28% in the absence of combination therapy (p = 0.07). For meningitis cases (n = 77), survival was greater for those receiving 3 or more antimicrobials over the course of treatment (3 of 4; 75%), compared to receipt of 1 or 2 antimicrobials (12 of 73; 16%) (p = 0.02). Median parenteral antimicrobial duration was 14 days. Combination bactericidal and protein synthesis inhibitor therapy may be appropriate in severe anthrax disease, particularly anthrax meningitis, in a mass casualty incident.
authors.forename: Satish K
authors.initials: SK
authors.lastname: Pillai
authors.forename: Eileen
authors.initials: E
authors.lastname: Huang
authors.forename: Julie T
authors.initials: JT
authors.lastname: Guarnizo
authors.forename: Jamechia D
authors.initials: JD
authors.lastname: Hoyle
authors.forename: Stefan
authors.initials: S
authors.lastname: Katharios-Lanwermeyer
authors.forename: Theresa K
authors.initials: TK
authors.lastname: Turski
authors.forename: William A
authors.initials: WA
authors.lastname: Bower
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Hendricks
authors.forename: Dana
authors.initials: D
authors.lastname: Meaney-Delman
mesh_terms: D061605:Administration, Intravenous; D000881:Anthrax / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000992:Antitoxins / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000379:methods* / Q000639:trends; D014943:Global Health; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D000992:Antitoxins